iShares MSCI Canada (TSX) vs Nuvalent Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.37, while Nuvalent Inc trades at $123.96 (market cap $9.81B). Which is the better fit depends on your goals.
| EWC | NUVL | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $59.49 | $123.96 |
52-Week Low | $45.86 | $72.16 |
Market Cap | — | $9.81B |
Enterprise Value | — | $8.52B |
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.32, up 0.24% today, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The stock shows strong support at $59 and resistance at $60. Recent corporate actions include a dividend scheduled for June 2026, while financial ratios are unavailable in the current data.
The outlook for EWC is mixed, with technical strength offset by overbought conditions. Investment opportunities hinge on sustained bullish momentum above $60, but risks include potential pullbacks from current highs and reliance on broader market trends given limited fundamental data.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.
The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.
Trailing returns across standard periods
Latest headlines on both assets
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →